- Home
- GORO vs TCRX Comparison
GORO vs TCRX Comparison
Compare GORO & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORO
- TCRX
- Stock Information
- Founded
- GORO 1998
- TCRX 2018
- Country
- GORO United States
- TCRX United States
- Employees
- GORO N/A
- TCRX N/A
- Industry
- GORO Precious Metals
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- GORO Basic Materials
- TCRX Health Care
- Exchange
- GORO Nasdaq
- TCRX Nasdaq
- Market Cap
- GORO 86.0M
- TCRX 90.5M
- IPO Year
- GORO N/A
- TCRX 2021
- Fundamental
- Price
- GORO $0.62
- TCRX $1.46
- Analyst Decision
- GORO Strong Buy
- TCRX Strong Buy
- Analyst Count
- GORO 1
- TCRX 6
- Target Price
- GORO $1.25
- TCRX $9.50
- AVG Volume (30 Days)
- GORO 1.3M
- TCRX 772.3K
- Earning Date
- GORO 05-12-2025
- TCRX 05-06-2025
- Dividend Yield
- GORO N/A
- TCRX N/A
- EPS Growth
- GORO N/A
- TCRX N/A
- EPS
- GORO N/A
- TCRX N/A
- Revenue
- GORO $59,378,000.00
- TCRX $4,421,000.00
- Revenue This Year
- GORO $68.69
- TCRX $68.86
- Revenue Next Year
- GORO $19.92
- TCRX $14.01
- P/E Ratio
- GORO N/A
- TCRX N/A
- Revenue Growth
- GORO N/A
- TCRX N/A
- 52 Week Low
- GORO $0.12
- TCRX $1.02
- 52 Week High
- GORO $0.74
- TCRX $9.29
- Technical
- Relative Strength Index (RSI)
- GORO 57.46
- TCRX 53.58
- Support Level
- GORO $0.52
- TCRX $1.39
- Resistance Level
- GORO $0.68
- TCRX $1.49
- Average True Range (ATR)
- GORO 0.06
- TCRX 0.11
- MACD
- GORO -0.01
- TCRX 0.02
- Stochastic Oscillator
- GORO 74.45
- TCRX 88.24
About GORO Gold Resource Corporation
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.